Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q7FM
|
|||
| Former ID |
DNC004148
|
|||
| Drug Name |
Azaperone
|
|||
| Synonyms |
Azaperone; 1649-18-9; Azaperon; Stresnil; Fluoperidol; Suicalm; Eucalmyl; Azeperone; Sedaperone vet; Azaperona; Azaperonum; R-1929; NSC 170976; Azaperonum [INN-Latin]; Azaperona [INN-Spanish]; 1-Butanone, 1-(4-fluorophenyl)-4-[4-(2-pyridinyl)-1-piperazinyl]-; UNII-19BV78AK7W; 1-(3-(4-Fluorobenzoyl)propyl)-4-(2-pyridyl)piperazine; CCRIS 1586; C19H22FN3O; 1-(4-Fluorophenyl)-4-[4-(2-pyridinyl)-1-piperazinyl]-1-butanone; 4'-Fluoro-4-(4-(2-pyridyl)-1-piperazinyl)butyrophenone; EINECS 216-715-8; R 1929; BRN 0565491; MLS003106751
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H22FN3O
|
|||
| Canonical SMILES |
C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=CC=CC=N3
|
|||
| InChI |
1S/C19H22FN3O/c20-17-8-6-16(7-9-17)18(24)4-3-11-22-12-14-23(15-13-22)19-5-1-2-10-21-19/h1-2,5-10H,3-4,11-15H2
|
|||
| InChIKey |
XTKDAFGWCDAMPY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1649-18-9
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:88301
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D2 receptor (D2R) | Target Info | Inhibitor | [1] |
| Dopamine D3 receptor (D3R) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Dopaminergic synapse | ||||
| Rap1 signaling pathway | ||||
| cAMP signaling pathway | ||||
| Gap junction | ||||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Nicotine pharmacodynamics pathway | ||||
| Reactome | Dopamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| Hypothetical Network for Drug Addiction | ||||
| Genes and (Common) Pathways Underlying Drug Addiction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors. J Med Chem. 1993 Nov 26;36(24):3929-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.